ESTRO 2025 - Abstract Book

S921

Clinical - Haematology

ESTRO 2025

4521

Mini-Oral Efficacy and toxicity of low dose radiotherapy for mucosa associated lymphoid tissue (MALT) lymphoma of the salivary glands Jessica L Brady 1 , Karen Stanley 2 , Mary Gleeson 2 , N G Mikhaeel 1,3 1 Department of Clinical Oncology, Guy's and St Thomas' Hospital, London, United Kingdom. 2 Department of Clinical Haematology, Guy's and St Thomas' Hospital, London, United Kingdom. 3 Department of Life Sciences and Medicine, King's College London University, London, United Kingdom Purpose/Objective: The salivary glands are the second most common site of MALT lymphoma. Salivary MALT has a strong association with Sjogren’s syndrome (SS), an autoimmune disorder which causes xerostomia. Low dose radiotherapy (LDRT) has been shown to be effective in several types of indolent lymphoma, achieving high local control with minimal toxicity, however its role in salivary MALT is not well-defined. LDRT is an attractive treatment option in this patient group as it may avoid worsening xerostomia. Here we evaluate outcomes following LDRT for salivary MALT lymphoma. Material/Methods: A retrospective review of patients who received LDRT for salivary MALT at our institution. Eligible patients were ≥ 18 with histologically confirmed MALT lymphoma of the parotid or submandibular glands or both and received LDRT, defined as 4Gy/2#, to one or more site . Patient, disease and treatment characteristics were recorded. Outcomes included overall response rate (ORR), local control, pattern of relapse, progression free survival (PFS) and overall survival (OS). Analysis was performed by course and by patient. Toxicity data was collected, including patient reported xerostomia. Results: Between December 2005 and November 2023, 44 courses of LDRT were delivered to 36 patients. Patient, disease and treatment characteristics are shown in Figure 1. Most patients were female and the majority (88.9%) had SS.